Study on the Effects of AZD5004 and Semaglutide for Adults with Type 2 Diabetes

2 1 1

What is this study about?

This clinical trial is focused on studying the effects of a new medication called AZD5004 in adults with Type 2 Diabetes Mellitus. The study aims to evaluate how well AZD5004 helps control blood sugar levels compared to a placebo. Participants will take the medication once daily in the form of a film-coated tablet for a period of 26 weeks.

In addition to AZD5004, the study will also involve the use of Rybelsus tablets, which contain the active substance semaglutide. These tablets come in doses of 3 mg, 7 mg, and 14 mg. The purpose of including Rybelsus is to compare its effects with those of AZD5004 and the placebo. The study will monitor changes in blood sugar levels, body weight, and other health indicators over the course of the trial.

Participants will be randomly assigned to receive either AZD5004, Rybelsus, or a placebo. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This approach helps ensure that the results are unbiased and reliable. The study will provide valuable information on the safety and effectiveness of AZD5004 in managing Type 2 Diabetes Mellitus.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying age, diagnosis of Type 2 Diabetes Mellitus for at least six months, and other health criteria.

The assessment ensures that the HbA1c level is between 7.0% and 10.5%, and that the patient has been managing diabetes with diet, exercise, or stable medication for at least one month.

2 randomization

Participants are randomly assigned to receive either the study medication AZD5004, a placebo, or an active comparator such as Rybelsus tablets.

The study is double-blind, meaning neither the participants nor the researchers know who receives which treatment.

3 medication administration

Participants take the assigned medication orally once daily for a duration of 26 weeks.

The medications include AZD5004 film-coated tablets or Rybelsus tablets in dosages of 3 mg, 7 mg, or 14 mg, depending on the group assignment.

4 monitoring and follow-up

Regular monitoring of blood sugar levels and other health indicators occurs at specified intervals: baseline, 4 weeks, 12 weeks, 16 weeks, and 26 weeks.

The primary goal is to observe changes in HbA1c levels, while secondary goals include changes in fasting glucose and body weight.

5 completion of study

At the end of the 26-week period, a final assessment is conducted to evaluate the overall effects of the treatment.

The study aims to determine the efficacy, safety, and tolerability of AZD5004 compared to placebo and other treatments.

Who Can Join the Study?

Adults who are 18 years or older.
Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 6 months. T2DM is a condition where the body doesn’t use insulin properly, leading to high blood sugar levels.
Have a blood test result called HbA1c between 7.0% and 10.5%. HbA1c is a measure of average blood sugar levels over the past 2 to 3 months.
Manage their diabetes with diet and exercise alone or with a stable dose of metformin or an SGLT2 inhibitor for at least one month before the study. Metformin and SGLT2 inhibitors are medications used to help control blood sugar levels.
Have a body mass index (BMI) of 23 kg/m² or higher. BMI is a number calculated from a person’s weight and height, used to assess if they have a healthy body weight.
Have had a stable body weight for 3 months before joining the study, meaning no more than a 5% change in body weight.
Are able to understand and sign a consent form and follow the study’s rules and requirements.

Who Cannot Join the Study?

Patients with a history of severe allergic reactions to any of the study medications.
Individuals who have had a recent heart attack or stroke.
Patients with uncontrolled high blood pressure.
Individuals with severe liver or kidney disease.
Patients who are currently pregnant or breastfeeding.
Individuals who are participating in another clinical trial.
Patients with a history of drug or alcohol abuse.
Individuals with any other medical condition that the study doctor believes would make participation unsafe.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.	Lodz	Poland
Niepublicznego Zakladu Opieki Zdrowotnej Specjalistyczny Osrodek Internistyczno Diabetologiczny	Bialystok	Poland
Ośrodek Badań Klinicznych “METABOLICA” lek. Robert Witek	Tarnow	Poland
Diabeteszentrum Hamburg West	Hamburg	Germany
PRAKTYKA LEKARSKA EWA KRZYŻAGÓRSKA	Poznan	Poland
Zentrum für klinische Studien Alexander Segner	St. Ingbert	Germany
Specjalistyczne Gabinety Lekarskie Landa	Cracow	Poland
Centrum Zdrowia Metabolicznego Paweł Bogdański	Poznan	Poland

Other Sites

Site Name	City	Country
Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet	Szolnok	Hungary
R.E.D. Institut fuer medizinische Studien und Fortbildung GmbH	Oldenburg In Holstein	Germany
InnoDiab Forschung GmbH	Essen	Germany
Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne Diab-Endo-Met Sp. z o.o.	Cracow	Poland
Medi-Dia s.r.o.	Sabinov	Slovakia
MediTask s.r.o.	Bratislava	Slovakia
Obudai Egeszseguegyi Centrum Kft.	Dunaújváros	Hungary
University Of Debrecen	Debrecen	Hungary
Areteus s.r.o.	Trebisov	Slovakia
Semmelweis University	Budapest	Hungary
Hospital Ruber Juan Bravo	Madrid	Spain
Salvia Lekston I Madej Sp. J.	Katowice	Poland
DIAB s.r.o.	Roznava	Slovakia
University Of Szeged	Szeged	Hungary
Zentrum für Klinische Forschung Allgäu Oberschwaben	Wangen im Allgäu	Germany
Institut fuer Diabetesforschung Muenster GmbH	Munster	Germany
Hospital Universitario Virgen De La Victoria	Malaga	Spain
Egytuz Svx z ovsi	Lublin	Poland
Rtjogbtmaicgkf Svy z oaji	Lodz	Poland
Drzdimbq sspnmm	Presov	Slovakia
Dxofqvem Sfuonjnvnypaaqrzg	Falkensee	Germany
Ccb Cucrkyib Rrscvkea Sfkxmbqp Mwpkrvbj Gloy	Mannheim	Germany
Hsaxqyxn Vuvf dmmhvxyd	Barcelona	Spain
Hvqzfusy Unkddaiqwzaxn dt A Cyscbx	A Coruna Galicia	Spain

Trial status

Country	Status	Recruitment Start
Germany	Not recruiting	11.03.2025
Hungary	Not recruiting	11.03.2025
Poland	Not recruiting	11.03.2025
Slovakia	Not recruiting	11.03.2025
Spain	Not recruiting	11.03.2025

Trial locations

Investigated drugs:

AZD5004 is a medication being studied for its potential to help control blood sugar levels in adults with Type 2 Diabetes Mellitus. The trial aims to assess how effective, safe, and tolerable this medication is compared to a placebo.

Investigated diseases:

Type 2 diabetes mellitus

Type 2 Diabetes Mellitus – This is a chronic condition that affects the way the body processes blood sugar (glucose). In this disease, the body either resists the effects of insulin, a hormone that regulates the movement of sugar into cells, or doesn’t produce enough insulin to maintain normal glucose levels. Over time, high blood sugar levels can lead to various health problems, including nerve damage, kidney issues, and vision problems. The progression of Type 2 Diabetes Mellitus can be gradual, often starting with insulin resistance and eventually leading to decreased insulin production. Lifestyle factors such as diet, physical activity, and weight management play a significant role in the development and progression of this condition. Regular monitoring of blood sugar levels is crucial to managing the disease effectively.

Trial ID:

2024-512562-34-00

Protocol code:

D7261C00001

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effects of AZD5004 and Semaglutide for Adults with Type 2 Diabetes

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?